Longwood Valley MedTech, a biopharmaceutical company based in Beijing E-Town, independently developed China's first AI-assisted bone health assessment medical product - AIVIEW® Artificial Intelligence Bone Health Assessment System, and China's first AI + sports injury assessment medical device product - AISM® Sports Injury Assessment System, filling the technological gaps in bone health and sports injury assessment in China.

These two products have been approved for launching in the market. The AI algorithms they rely on have enhanced the precision and efficiency of medical image processing, providing doctors with clearer evaluation criteria.

The AIVIEW® Artificial Intelligence Bone Health Assessment System integrates cutting-edge AI technologies such as deep learning and computer vision. In clinical practice, the AI system, trained and learned through a large amount of medical imaging data, can quickly and accurately perform AI intelligent evaluation and analysis based on X-ray data of hip and knee joints. It generates imaging reports in conjunction with authoritative guidelines, assists physicians in image reading, measurements, and report writing, identifies potential signs of lesions, provides doctors with scientific and objective auxiliary assessment information, achieves early detection of bone and joint diseases, enables early prevention, early assessment, and reduces the burden of disease on patients.

In addition, the AISM® Sports Injury Assessment System combines artificial intelligence deep learning with medical big data to achieve three-dimensional reconstruction of the knee joint, intelligent segmentation, intelligent recognition, precise measurement, and determination of bone tunnel position, accurate and efficient preoperative assessment, surgical simulation, and intelligent output of ACL reconstruction surgical plans.